Rubix LS has joined the federal consortium of industry partners to fully develop plans and strategies for mobilizing robust response measures toward the growing COVID-19 worldwide pandemic in the United States.
Rubix LS is joined by countless other firms, within the U.S, to fight against the emerging infectious pathogen that has now spanned across 120 countries globally. The effort involved is to ensure that adequate resources, test kits, innovations, and other services are provided to public institutions and hospitals to be ready for the growing infected population.
Part of the responsibility of Rubix LS engagement will be to ensure that a suitable vaccine candidate can be accelerated towards clinical trials.